Sign In
Buy ATHX
$0.0135
+0 (+0%)
At Close: Apr 05, 2024
Athersys to Host a Virtual Investor Day
06:00am, Thursday, 28'th Jan 2021
CLEVELAND, Ohio--(BUSINESS WIRE)---- $ATHX #Athersys--Athersys will host a virtual investor day event on February 16th to cover development progress and commercial manufacturing plans.
Athersys (ATHX) Surges: Stock Moves 8.8% Higher
09:47am, Friday, 08'th Jan 2021
Athersys (ATHX) saw a big move last session, as its shares jumped nearly 9% on the day, amid huge volumes.
Why Athersys Stock Jumped Today
03:41pm, Monday, 21'st Dec 2020
The biotech announced the enrollment of the first patient in a key clinical study.
CLEVELAND--(BUSINESS WIRE)---- $ATHX #Athersys--UTHealth and Athersys announce patient enrollment in an innovative clinical study of MultiStem® cell therapy for the treatment of traumatic injuries
Athersys Announces Three Appointments to Board of Directors
06:00am, Monday, 16'th Nov 2020
CLEVELAND--(BUSINESS WIRE)---- $ATHX #Athersys--Athersys announces three appointments to its board of directors, deepening board expertise to prepare for future growth and commercialization.
Athersys, Inc.'s (ATHX) CEO Gil Van Bokkelen on Q3 2020 Results - Earnings Call Transcript
08:49pm, Monday, 09'th Nov 2020
Athersys, Inc.'s (ATHX) CEO Gil Van Bokkelen on Q3 2020 Results - Earnings Call Transcript
Athersys, Inc. (ATHX) CEO Gil Van Bokkelen On Q3 2020 Results - Quick Version Earnings Call Transcript
07:15pm, Monday, 09'th Nov 2020
Athersys, Inc. (ATHX) CEO Gil Van Bokkelen On Q3 2020 Results - Quick Version Earnings Call Transcript
Athersys to Host Third Quarter Financial Results Call
12:00am, Thursday, 08'th Oct 2020
Athersys, Inc. (Nasdaq: ATHX) will release its third quarter 2020 financial results on Monday, November 9, 2020.
FDA Grants RMAT Designation to MultiStem Cell Therapy for the Treatment of Acute Respiratory Distress Syndrome
12:00am, Wednesday, 23'rd Sep 2020
MultiStem is the only cell therapy program for acute respiratory distress syndrome (ARDS) that has both Fast Track and RMAT designation from the FDA.
Athersys: Still An Abundance Of Opportunity
09:28am, Tuesday, 01'st Sep 2020
Late-stage pivotal programs continue to progress in COVID-19 environment. Federal funding for MACOVIA trial is still in play.
Athersys (ATHX) Q2 2020 Earnings Call Transcript
06:00am, Tuesday, 11'th Aug 2020
Thank you for standing by, and welcome to the Athersys second-quarter 2020 results Conference Call. As Jesse mentioned, I'm Karen Hunady, director of corporate communications and investor relations f
Athersys, Inc. (ATHX) CEO Gil Van Bokkelen on Q2 2020 Results - Earnings Call Transcript
03:17am, Tuesday, 11'th Aug 2020
Athersys, Inc. (NASDAQ:ATHX) Q2 2020 Earnings Conference Call August 10, 2020 16:30 ET Company Participants Karen Hunady - Director of Corporate Communications and Investor Relations Ivor Macleod - Ch
Athersys Reports Second Quarter 2020 Results
08:00pm, Monday, 10'th Aug 2020
Athersys has made progress during Q2 in key clinical programs and infrastructure to support its planned transition to becoming a commercial company.
Athersys Reports Second Quarter 2020 Results
12:00am, Monday, 10'th Aug 2020
Athersys has made progress during Q2 in key clinical programs and infrastructure to support its planned transition to becoming a commercial company.
The Week Ahead In Biotech: Bausch Health, Fennec Pharma FDA Decisions And Smid-cap Earnings
12:00am, Sunday, 09'th Aug 2020
Biotech stocks advanced in the week ended Aug. 7, buoyed by multiple catalysts. Aside from the broader market strength, mostly positive earnings and continuing coronavirus...
